earnings
confidence high
sentiment neutral
materiality 0.75
Pacira Q3 total rev $179.5M (+6% YoY); GAAP net income $5.4M vs loss; guides FY rev lower, gross margin higher
Pacira BioSciences, Inc.
2025-Q3 EPS reported
$0.12
revenue$529,538,000
- Total revenues $179.5M, up 6% YoY; EXPAREL $139.9M (volume +9% offset by mix and discounting).
- GAAP net income $5.4M ($0.12/share) vs net loss of $143.5M in Q3 2024, which included $163.2M goodwill impairment.
- Adjusted EBITDA $49.4M vs $54.7M; non-GAAP net income $31.8M ($0.72 diluted) vs $38.2M ($0.79) prior year.
- FY2025 revenue guidance lowered to $725-735M from $730-750M; non-GAAP gross margin raised to 80-82% from 78-80%.
- Repurchased 2.0M shares for $50M; $200M remaining on authorization; exclusive license of AMT-143 (ropivacaine) with $5M upfront.